Business Wire

Adtran’s Coherent 100ZR and FSP 3000 OLS to play key role in OIF’s ECOC open interoperability showcase

20.9.2024 14:00:00 CEST | Business Wire | Press release

Share

News summary: Adtran FSP 3000 open optical line system facilitates transport of coherent 100ZR and 400G OpenZR+ interfaces in OIF multi-vendor demo Demo spanning nearly 300km also features Adtran’s Coherent 100ZR QSFP28 pluggable transceiver for cost-effective, low-power 100G transport Collaboration with leading industry players highlights Adtran’s role in driving open, scalable optical networking solutions

Adtran today announced its key role in the Optical Internetworking Forum’s (OIF) demonstration of open, multi-vendor networking at the European Conference on Optical Communication (ECOC) 2024. At the center of the showcase are Adtran’s Coherent 100ZR QSFP28 pluggable module and its FSP 3000 open optical line system (OLS), which enables the transport of a wide range of data rates, including 100ZR and 400Gbit/s OpenZR+, as featured in this demo. Incorporating 100Gbit/s to 800Gbit/s coherent pluggable transceivers and various OLS technologies from multiple vendors, the demo showcases advancements in open optical networking and innovative vendor-neutral solutions, highlighting the importance of testing multi-vendor interoperability.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240920990844/en/

Adtran’s central role in the OIF demo underlines its commitment to developing open solutions that seamlessly interoperate with other vendors. (Photo: Business Wire)

“Adtran continues to lead the way in promoting open, disaggregated networking. By integrating our FSP 3000 OLS with 100ZR and 400Gbit/s OpenZR+ transceivers from a wide range of vendors, including our coherent 100ZR QSFP28, we’re offering operators a cost-effective, low-power solution to enhance their data center interconnect (DCI) networks and cloud infrastructure. With its standards-compliant design, our coherent 100ZR facilitates multi-vendor interoperability for 100Gbit/s transmission up to 300km over any open line system, while the FSP 3000 OLS streamlines operations and ensures flexible, scalable transport with optimal performance,” said Christoph Glingener, CTO of Adtran. “This collaboration with the OIF and other major industry players demonstrates our commitment to providing open solutions that meet the evolving demands of the cloud and the optical edge.”

The joint solution on display showcases exceptional optical performance, with the Adtran FSP 3000 OLS ensuring streamlined setup and precise operation. Equipped with integrated monitoring and diagnostic functions, as well as a high level of automation, the FSP 3000 OLS simplifies management and optimizes transmission performance. The collaboration with industry leaders highlights Adtran’s commitment to open optical networking solutions and demonstrates how its technology is built to industry standards. This approach offers the flexibility and scalability needed to meet diverse customer requirements while advancing multi-vendor interoperability.

“For decades, we’ve been pioneers in the DCI space, enabling enterprises and cloud providers to build high-capacity, high-performance networks. Our solutions are built around an open environment, promoting innovation and seamless interoperability with other vendors. We’re proud to be at the heart of this large-scale demonstration, where our Coherent 100ZR and FSP 3000 OLS are driving the adoption of open, multi-vendor interoperability for data center applications,” commented Stephan Neidlinger, VP of global business development at Adtran. “By championing openness and collaboration across the industry, we’re advancing high-performance networking and reaffirming our leadership in delivering the technologies that will shape the future of optical networking.”

Visitors to ECOC can find out more about the demo at Adtran’s booth, D79, and the OIF’s booth, B83.

OIF Champions Interoperability at ECOC 2024: 34 Member Companies to Showcase Solutions for Data Centers, AI/ML Technologies and Disaggregated Systems

At ECOC 2024, OIF will host a dynamic interoperability demonstration, featuring live collaboration from 34 member companies shaping the future of connectivity. This showcase will highlight advanced solutions that are redefining performance, efficiency and capacity in response to the burgeoning needs of future-oriented data centers, AI/ML technologies and disaggregated systems. Attendees will discover cutting-edge interoperability solutions in 800ZR, 400ZR and Multi-span optics, along with innovations in Energy Efficient Interfaces (EEI) & Co-Packaging, 224G and 112G Common Electrical I/O (CEI) and Common Management Interface Specification (CMIS) that are crucial for shaping the next decade of industry standards. Visit us at booth #B83 for live, interactive demonstrations. For further details, please visit: https://www.oiforum.com/meetings-events/oif-ecoc-2024.

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by

ADTRAN Holdings, Inc.

www.adtran.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240920990844/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye